- Home
- MUJ vs URGN Comparison
MUJ vs URGN Comparison
Compare MUJ & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- URGN
- Stock Information
- Founded
- MUJ 1998
- URGN 2004
- Country
- MUJ United States
- URGN United States
- Employees
- MUJ N/A
- URGN N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- URGN Health Care
- Exchange
- MUJ Nasdaq
- URGN Nasdaq
- Market Cap
- MUJ 573.3M
- URGN 465.9M
- IPO Year
- MUJ N/A
- URGN 2017
- Fundamental
- Price
- MUJ $10.81
- URGN $9.67
- Analyst Decision
- MUJ
- URGN Strong Buy
- Analyst Count
- MUJ 0
- URGN 7
- Target Price
- MUJ N/A
- URGN $37.21
- AVG Volume (30 Days)
- MUJ 108.0K
- URGN 499.1K
- Earning Date
- MUJ 01-01-0001
- URGN 05-12-2025
- Dividend Yield
- MUJ 4.36%
- URGN N/A
- EPS Growth
- MUJ N/A
- URGN N/A
- EPS
- MUJ N/A
- URGN N/A
- Revenue
- MUJ N/A
- URGN $90,398,000.00
- Revenue This Year
- MUJ N/A
- URGN $38.65
- Revenue Next Year
- MUJ N/A
- URGN $118.69
- P/E Ratio
- MUJ N/A
- URGN N/A
- Revenue Growth
- MUJ N/A
- URGN 9.29
- 52 Week Low
- MUJ $9.74
- URGN $8.94
- 52 Week High
- MUJ $11.70
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- MUJ 35.03
- URGN 41.45
- Support Level
- MUJ $10.50
- URGN $8.94
- Resistance Level
- MUJ $10.95
- URGN $10.83
- Average True Range (ATR)
- MUJ 0.19
- URGN 0.79
- MACD
- MUJ -0.02
- URGN -0.07
- Stochastic Oscillator
- MUJ 33.33
- URGN 29.67
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.